Production (Stage)
Aquestive Therapeutics, Inc.
AQST
$2.35
$0.062.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.24M | -44.14M | -35.19M | -25.72M | -28.77M |
| Total Depreciation and Amortization | 673.00K | 741.00K | 1.07M | 1.17M | 1.25M |
| Total Amortization of Deferred Charges | 10.79M | 10.71M | 9.81M | 7.20M | 4.59M |
| Total Other Non-Cash Items | 6.90M | 6.88M | 6.44M | 5.62M | 5.02M |
| Change in Net Operating Assets | -12.90M | -9.96M | -16.34M | -12.95M | -7.67M |
| Cash from Operations | -48.78M | -35.76M | -34.21M | -24.68M | -25.58M |
| Capital Expenditure | -265.00K | -159.00K | -160.00K | -231.00K | -1.02M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -265.00K | -159.00K | -160.00K | -231.00K | -1.02M |
| Total Debt Issued | -- | -- | 31.14M | 31.14M | 31.14M |
| Total Debt Repaid | -24.00K | -23.00K | -39.00M | -39.00M | -42.45M |
| Issuance of Common Stock | 23.44M | 84.72M | 88.17M | 92.96M | 98.98M |
| Repurchase of Common Stock | -911.00K | -1.10M | -1.10M | -898.00K | -896.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -10.00K | -5.00K | 8.14M | 8.14M | 8.14M |
| Cash from Financing | 22.50M | 83.59M | 87.35M | 92.34M | 94.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.54M | 47.67M | 52.98M | 67.43M | 68.32M |